Replicor Inc., 6100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada.
Viruses. 2021 Apr 23;13(5):745. doi: 10.3390/v13050745.
While current therapies for chronic HBV infection work well to control viremia and stop the progression of liver disease, the preferred outcome of therapy is the restoration of immune control of HBV infection, allowing therapy to be removed while maintaining effective suppression of infection and reversal of liver damage. This "functional cure" of chronic HBV infection is characterized by the absence of detectable viremia (HBV DNA) and antigenemia (HBsAg) and normal liver function and is the goal of new therapies in development. Functional cure requires removal of the ability of infected cells in the liver to produce the hepatitis B surface antigen. The increased observation of transaminase elevations with new therapies makes understanding the safety and therapeutic impact of these flares an increasingly important issue. This review examines the factors driving the appearance of transaminase elevations during therapy of chronic HBV infection and the interplay of these factors in assessing the safety and beneficial nature of these flares.
虽然目前治疗慢性乙型肝炎病毒感染的方法能很好地控制病毒血症并阻止肝病进展，但治疗的首选结果是恢复对乙型肝炎病毒感染的免疫控制，从而在维持有效抑制感染和逆转肝损伤的同时停用治疗药物。这种慢性乙型肝炎病毒感染的“功能性治愈”的特征是检测不到病毒血症（HBV DNA）和抗原血症（HBsAg）以及正常的肝功能，是新疗法开发的目标。功能性治愈需要消除肝脏感染细胞产生乙型肝炎表面抗原的能力。随着新疗法的应用，观察到转氨升高的情况越来越多，因此了解这些升高的安全性和治疗影响成为一个日益重要的问题。这篇综述探讨了在慢性乙型肝炎病毒感染治疗过程中转氨酶升高的驱动因素，以及这些因素在评估这些升高的安全性和有益性方面的相互作用。
